Trastuzumab Deruxtecan Plus Pertuzumab Reduce a Risk of Progression or Death in First-Line Treatment for HER2-positive Advanced or Metastatic Breast Cancer By Ogkologos - November 3, 2025 80 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the DESTINY-Breast09 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Accordpharma Enzalutamide Ahead of ESMO Immuno-Oncology Congress 2025: topics at a glance Aiming to Prevent Cancer Cases, ESMO Calls Against Misleading Alcohol-Labelling Following European Parliament Vote on the EU Wine Package MOST POPULAR Lack of Benefit of Adding Immune Checkpoint Inhibitors to Chemotherapy in... December 6, 2021 ESMO Calls for Oncology-Specific Safeguards in EU Joint Clinical Assessments of... July 1, 2025 EMA Recommends Granting a Conditional Marketing Authorisation for Mosunetuzumab May 17, 2022 How targeted screening can help the NHS save lives from lung... November 23, 2022 Load more HOT NEWS How the history of medicine influenced our perception of cancer New Year’s Wishes 2016 Bowel scope screening to stop in England Little Girl Declared Cancer-Free For The Holidays Following 2 Years Of...
